Amylyx Pharmaceuticals, Inc.
AMLX • NASDAQ
Amylyx Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Joshua Cohen, with a market cap of $1.5B.
CEOJoshua Cohen
Next Earnings
Upcoming earnings announcement for Amylyx Pharmaceuticals, Inc.
Date
Thursday, May 7, 2026 (in a month)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.34
Earnings History
Past 12 earnings reports for Amylyx Pharmaceuticals, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Q4 2025 | -$0.30Est: -$0.33 | +9.1% | - | — |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.37Est: -$0.43 | +14.0% | - | — | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.46Est: -$0.45 | -2.2% | - | — | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.42Est: -$0.50 | +16.0% | - | — | 10-Q |
| Mar 4, 2025 | Q4 2024 | -$0.55Est: -$0.59 | +6.8% | -$665.0K | — | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.53Est: -$0.71 | +25.4% | $416.0K | — | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.73Est: -$0.73 | 0.0% | -$1.2MEst: $10.7M | -111.3% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.12Est: -$0.01 | -1100.0% | $88.6MEst: $98.4M | -9.9% | 10-Q |
| Feb 22, 2024 | Q4 2023 | $0.07Est: $0.23 | -69.6% | $108.4MEst: $107.0M | +1.4% | 10-K |
| Nov 9, 2023 | Q3 2023 | $0.30Est: $0.44 | -31.8% | $102.7MEst: $114.3M | -10.1% | — |
| Aug 10, 2023 | Q2 2023 | $0.31Est: $0.10 | +210.0% | $98.2MEst: $92.1M | +6.6% | 10-Q |
| May 11, 2023 | Q1 2023 | $0.02 | — | $71.4MEst: $59.0M | +21.1% | — |